SG3 Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

SG3 Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$163K	–	444
2022 Q1	$163K	Sell	10,000 -20,000	-67%	-$321K	﹤0.01%	788
2021 Q4	$416K	Buy	30,000 +6,500	+28%	+$86K	0.01%	673
2021 Q3	$338K	Buy	+23,500	New	+$371K	0.01%	682
2021 Q2	–	Sell	-30,000	Closed	-$305K	–	1026
2021 Q1	$305K	Sell	30,000 -75,000	-71%	-$773K	0.01%	883
2020 Q4	$782K	Hold	105,000	–	–	0.01%	615
2020 Q3	$361K	Buy	+105,000	New	+$450K	0.01%	626

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return